Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested a drug called WVE-120102 in 36 people across three starting dose groups — 8 people began on 4 mg, 10 on 8 mg, and 18 on 16 mg. During the trial, many participants had their doses increased over time, with some eventually receiving 32 mg. The trial was measuring safety and tolerability — in other words, it was tracking what kinds of unwanted health events occurred while people were taking the drug and at what doses. Notably, none of the 36 participants completed the trial; all either withdrew or did not finish for other reasons. The reported data shows that across all dose groups, a number of participants experienced what are called "treatment-emergent adverse events" (TEAEs) — these are unwanted health events that occurred during the treatment period. In the 4 mg group, 7 out of 8 participants had at least one such event; in the 8 mg group, 14 participants; in the 16 mg group, 34 participants; and in the 32 mg group, 17 participants. The reported data also shows that more severe events were recorded at higher doses — no participants in the 4 mg or 8 mg groups had a severe event, while 2 in the 16 mg group and 5 in the 32 mg group did. Serious adverse events (a specific medical category for events requiring significant attention) were reported in 0, 1, 5, and 3 participants across the four dose groups respectively. A total of 4 participants withdrew from the trial due to these events (0, 1, 3, and 0 across the dose groups). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You previously completed the earlier phase of this study (called WVE-HDSNP2-001) using the drug WVE-120102.
Who may not be able to join:
- You have taken another experimental drug (other than WVE-120102) in the past year, or within a certain period based on how long that drug stays in your body — whichever is longer.
- You are unable to have a brain MRI scan, even with the help of sedation (medication to help you relax or sleep during the scan).
- You have a significant health condition other than Huntington's disease that the study doctor believes would make it unsafe or difficult for you to complete the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, MD, WAVE Life Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety: Number of Patients With Treatment-emergent Adverse Events (TEAEs); Safety: Number of Patients With a Severe TEAE; Safety: Number of Patients With Serious TEAEs; Safety and Tolerability: Number of Patients Who Withdraw Due to TEAEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.